These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 19439741)

  • 1. Adjuvant chemotherapy in older women with early-stage breast cancer.
    Muss HB; Berry DA; Cirrincione CT; Theodoulou M; Mauer AM; Kornblith AB; Partridge AH; Dressler LG; Cohen HJ; Becker HP; Kartcheske PA; Wheeler JD; Perez EA; Wolff AC; Gralow JR; Burstein HJ; Mahmood AA; Magrinat G; Parker BA; Hart RD; Grenier D; Norton L; Hudis CA; Winer EP;
    N Engl J Med; 2009 May; 360(20):2055-65. PubMed ID: 19439741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Adjuvant chemotherapy in older women with breast cancer. CALGB Study (The Cancer and Leukemia Group B Study)].
    Mallmann P; Nitschmann S
    Internist (Berl); 2010 Jul; 51(7):923-4. PubMed ID: 20544172
    [No Abstract]   [Full Text] [Related]  

  • 3. Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907.
    Kornblith AB; Lan L; Archer L; Partridge A; Kimmick G; Hudis C; Winer E; Casey R; Bennett S; Cohen HJ; Muss HB
    J Clin Oncol; 2011 Mar; 29(8):1022-8. PubMed ID: 21300923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
    Muss HB; Polley MC; Berry DA; Liu H; Cirrincione CT; Theodoulou M; Mauer AM; Kornblith AB; Partridge AH; Dressler LG; Cohen HJ; Kartcheske PA; Perez EA; Wolff AC; Gralow JR; Burstein HJ; Mahmood AA; Sutton LM; Magrinat G; Parker BA; Hart RD; Grenier D; Hurria A; Jatoi A; Norton L; Hudis CA; Winer EP; Carey L
    J Clin Oncol; 2019 Sep; 37(26):2338-2348. PubMed ID: 31339827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
    Cameron D; Morden JP; Canney P; Velikova G; Coleman R; Bartlett J; Agrawal R; Banerji J; Bertelli G; Bloomfield D; Brunt AM; Earl H; Ellis P; Gaunt C; Gillman A; Hearfield N; Laing R; Murray N; Couper N; Stein RC; Verrill M; Wardley A; Barrett-Lee P; Bliss JM;
    Lancet Oncol; 2017 Jul; 18(7):929-945. PubMed ID: 28600210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.
    Stockler MR; Harvey VJ; Francis PA; Byrne MJ; Ackland SP; Fitzharris B; Van Hazel G; Wilcken NR; Grimison PS; Nowak AK; Gainford MC; Fong A; Paksec L; Sourjina T; Zannino D; Gebski V; Simes RJ; Forbes JF; Coates AS
    J Clin Oncol; 2011 Dec; 29(34):4498-504. PubMed ID: 22025143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy: Adjuvant chemotherapy in older patients with breast cancer.
    Jager A; Verweij J; Sleijfer S
    Nat Rev Clin Oncol; 2009 Oct; 6(10):563-5. PubMed ID: 19786999
    [No Abstract]   [Full Text] [Related]  

  • 8. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.
    Partridge AH; Archer L; Kornblith AB; Gralow J; Grenier D; Perez E; Wolff AC; Wang X; Kastrissios H; Berry D; Hudis C; Winer E; Muss H
    J Clin Oncol; 2010 May; 28(14):2418-22. PubMed ID: 20368559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907).
    Ruddy KJ; Pitcher BN; Archer LE; Cohen HJ; Winer EP; Hudis CA; Muss HB; Partridge AH
    Ann Oncol; 2012 Dec; 23(12):3075-3081. PubMed ID: 22767584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
    von Minckwitz G; K├╝mmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
    J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.
    Smorenburg CH; de Groot SM; van Leeuwen-Stok AE; Hamaker ME; Wymenga AN; de Graaf H; de Jongh FE; Braun JJ; Los M; Maartense E; van Tinteren H; Nortier JWR; Seynaeve C
    Ann Oncol; 2014 Mar; 25(3):599-605. PubMed ID: 24504445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
    Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
    Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
    Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
    Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
    Martin M; Villar A; Sole-Calvo A; Gonzalez R; Massuti B; Lizon J; Camps C; Carrato A; Casado A; Candel MT; Albanell J; Aranda J; Munarriz B; Campbell J; Diaz-Rubio E;
    Ann Oncol; 2003 Jun; 14(6):833-42. PubMed ID: 12796019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group
    J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
    Oshaughnessy JA; Blum J; Moiseyenko V; Jones SE; Miles D; Bell D; Rosso R; Mauriac L; Osterwalder B; Burger HU; Laws S
    Ann Oncol; 2001 Sep; 12(9):1247-54. PubMed ID: 11697835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
    Geyer CE; Forster J; Lindquist D; Chan S; Romieu CG; Pienkowski T; Jagiello-Gruszfeld A; Crown J; Chan A; Kaufman B; Skarlos D; Campone M; Davidson N; Berger M; Oliva C; Rubin SD; Stein S; Cameron D
    N Engl J Med; 2006 Dec; 355(26):2733-43. PubMed ID: 17192538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
    Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
    Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer. Updated results.
    Zambetti M; Valagussa P; Bonadonna G
    Ann Oncol; 1996 Jul; 7(5):481-5. PubMed ID: 8839902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.